Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine for Pain After PCNL
NCT03043027Phase 3Withdrawn
- Sponsor
- Northwell Health
- Start
- Aug 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of liposomal bupivacaine in postoperative pain (3 arms), sponsored by Northwell Health. Primary endpoint: Visual Analog Scale Pain Score at 24 hours. Planned start Aug 2017; status: withdrawn.
02
Drugs
liposomal bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT03043027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03043027.